A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

The primary objective of the study is to evaluate the dose response of bimekizumab (also known as UCB4940) administered subcutaneously (sc) every 4 weeks (Q4W) for 12 weeks in the treatment of subjects with moderate to severe chronic plaque psoriasis.

Primary Sponsor:
UCB Biopharma

Prinicipal Investigator:
Alison Ehrlich, MD/Dermatology

Contact Phone:
202-677-6160

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):